Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. RemeGen Co., Ltd.
  6. News
  7. Summary
    9995   CNE1000048G6

REMEGEN CO., LTD.

(9995)
  Report
Delayed Hong Kong Stock Exchange  -  04:08 2022-06-30 am EDT
43.95 HKD   +5.90%
05/05RemeGen Co., Ltd. Approves Appointment of Chen Yunjin as Independent Non-Executive Director
CI
04/28RemeGen Widens Q1 Loss as R&D, Selling Expenses Balloon
MT
04/27RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

RemeGen Turns to Profit in 2021 on Launch of Core Autoimmune, Cancer Drugs; Shares Rise 3%

02/20/2022 | 11:35pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
REMEGEN CO., LTD. 5.90% 43.95 Delayed Quote.-43.58%
SEAGEN INC. 1.79% 180.11 Delayed Quote.16.50%
UNITED STATES DOLLAR (B) / CHINESE YUAN IN HONG KONG (USD/CNH) 0.10% 6.7 Delayed Quote.5.30%
All news about REMEGEN CO., LTD.
05/05RemeGen Co., Ltd. Approves Appointment of Chen Yunjin as Independent Non-Executive Dire..
CI
04/28RemeGen Widens Q1 Loss as R&D, Selling Expenses Balloon
MT
04/27RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/12RemeGen Co., Ltd. Announces Executive Changes
CI
04/11UBS Upgrades RemeGen to Buy From Neutral, Adjusts Price Target to HK$75.03 From HK$108
MT
03/31RemeGen Lists in Shanghai's STAR Market
MT
03/22RemeGen Prices Shanghai IPO to Raise $410 Million
MT
02/20RemeGen Turns to Profit in 2021 on Launch of Core Autoimmune, Cancer Drugs; Shares Rise..
MT
02/20RemeGen Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 20..
CI
01/25Remegen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of ..
CI
More news
Analyst Recommendations on REMEGEN CO., LTD.
More recommendations
Financials
Sales 2022 951 M 142 M 142 M
Net income 2022 -975 M -146 M -146 M
Net cash 2022 2 331 M 348 M 348 M
P/E ratio 2022 -19,7x
Yield 2022 -
Capitalization 24 027 M 3 587 M 3 586 M
EV / Sales 2022 22,8x
EV / Sales 2023 10,6x
Nbr of Employees 2 121
Free-Float 48,7%
Chart REMEGEN CO., LTD.
Duration : Period :
RemeGen Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REMEGEN CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 37,52 CNY
Average target price 60,61 CNY
Spread / Average Target 61,6%
EPS Revisions
Managers and Directors
Jian Min Fang CEO, Executive Director & Chief Scientific Officer
Dao Tian Fu President
Jia Li Chief Financial Officer & Joint Secretary
Weidong Wang Chairman
Ruyi He Executive Director & Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
REMEGEN CO., LTD.-43.58%3 587
GILEAD SCIENCES, INC.-14.12%78 219
VERTEX PHARMACEUTICALS30.84%73 484
REGENERON PHARMACEUTICALS, INC.-5.72%64 152
WUXI APPTEC CO., LTD.-13.31%44 566
BIONTECH SE-38.91%38 276